UPDATE: Seattle Genetics Says Results From Patients Treated in North America Demonstrate 2-Year Modified Progression-Free Survival of 84.3% in the ADCETRIS Combination Arm Compared to 73.7% in the ABVD Arm
Benzinga Newsdesk